Kiniksa Pharmaceuticals, Ltd.KNSANASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank22
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P22
Within normal range
vs 2Y Ago
-0.8x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2025-13.23%
202446.69%
202316.20%
2022-34.05%
2021-9.43%
2020-17.52%
201953.51%
201853.66%
2017223.17%
20160.00%